MediLink Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of YL217

July 2, 2025 – MediLink Therapeutics, a clinical-stage biotechnology company, today announced that the first patient has been enrolled and dosed in China in the Global Phase I clinical trial of YL217. YL217 is a CDH17-targeting antibody-drug conjugate (ADC) based on MediLink’s proprietary TMALIN® technology platform.

MediLinks Appoints Dr. Weichang Zhou as Chief Technology Officer

MediLink Announces YL201 Granted Breakthrough Therapy Designation by FDA

June 23, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to YL201 for the treatment of small cell lung cancer (SCLC). YL201 is an investigational B7H3-targeted antibody drug conjugate (ADC) developed based on MediLink’s proprietary TMALIN® (Tumor Microenvironment Activable LINker) technology platform.